• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Leap Therapeutics Inc.

    11/6/24 4:31:33 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LPTX alert in real time by email
    S-8 1 tm2427556d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on November 6, 2024 

    Registration No. 333- __________

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    Leap Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   27-4412575

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS Employer

    Identification No.)

     

    47 Thorndike Street

    Suite B1-1

    Cambridge, MA 02141

    Telephone: (617) 714-0360

    (Address of principal executive offices) (Zip Code)

     

    Leap Therapeutics, Inc. 2022 Equity Incentive Plan, as amended

    (Full title of the Plan)

     

     

    Douglas E. Onsi

    Chief Executive Officer and President

    Leap Therapeutics, Inc.

    47 Thorndike Street, Suite B1-1

    Cambridge, MA 02141

    (Name and address of agent for service)

     

    (617) 714-0360

    (Telephone number, including area code, of agent for service)

     

     

    Copy to:

     

    Julio E. Vega, Esq.

    Morgan, Lewis & Bockius LLP

    One Federal Street

    Boston, MA 02110

    (617) 951-8901

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
             
    Non-accelerated filer x   Smaller reporting company x
             
          Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Leap Therapeutics, Inc. (the “Registrant”) for the purpose of registering an additional 2,000,000 shares of common stock, par value $0.001 per share, of the Registrant (the “Common Stock”) to be offered to eligible persons under the Registrant’s 2022 Equity Incentive Plan, which was originally adopted at the annual meeting of the Registrant’s shareholders on June 16, 2022, and was subsequently amended as of June 16, 2023 and July 2, 2024 (as amended to date, the “2022 Plan”).

     

    On April 25, 2024, an amendment to the 2022 Plan (in the form then in effect) was approved by the board of directors of the Registrant and was subsequently approved by the Registrant’s shareholders at its annual meeting on July 2, 2024 to increase the number of shares of Common Stock reserved for issuance under the 2022 Plan by an additional 2,000,000 shares.

     

    The shares of Common Stock registered hereby are in addition to and of the same class as those on the Registrant’s registration statements on Form S-8 registering (i) 7,500,000 shares of Common Stock issuable under the 2022 Plan previously filed with the Securities and Exchange Commission (the “Commission”) on August 17, 2022 (SEC File No. 333-266944) and (ii) 2,250,000 shares of Common Stock issuable under the 2022 Plan previously filed with the Commission on August 30, 2023 (SEC File No. 333-274270) (the “Prior Registration Statement”). This Registration Statement is submitted in accordance with General Instruction E of Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statement are incorporated herein by reference and made part of this Registration Statement, except for Items 3 and 8, which are being updated by this Registration Statement below.

     

     

     

     

    PART II

     

    INCORPORATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.


    The following documents, which have been previously filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are hereby incorporated herein by reference and shall be deemed to be a part of this Registration Statement:

     

    (1) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on March 18, 2024;

     

    (2) The Registrant’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2024, filed with the Commission on May 13, 2024 and the quarter ended June 30, 2024, filed with the Commission on August 12, 2024;

     

    (3) The Registrant’s Current Reports on Form 8-K filed with the Commission on January 16, 2024, January 23, 2024, April 11, 2024, July 8, 2024 and September 30, 2024 (provided that any portions of such reports that are deemed furnished and not filed pursuant to instructions to Form 8-K shall not be incorporated by reference into this Registration Statement); and

     

    (4) The description of Common Stock set forth in Exhibit 4.6 to the Registrant’s Annual Report on Form 10-K filed with the Commission on March 16, 2020 pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

     

    In addition, all documents that the Registrant files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of this Registration Statement (except for any portions of the Registrant’s Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission), but prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing such documents.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit Number   Exhibit
         
    5.1    Opinion of Morgan, Lewis & Bockius LLP.
    23.1   Consent of EisnerAmper LLP, Independent Registered Public Accounting Firm.
    23.2   Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1).
    24.1   Powers of Attorney (included on the signature page of this Registration Statement on Form S-8).
    99.1   Leap Therapeutics, Inc. 2022 Equity Incentive Plan, as amended (incorporated by reference to Annex A of the Registrant’s Form DEF 14A filed with the Commission on April 29, 2024).
    107   Filing Fee Table

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts on November 6, 2024.

     

      LEAP THERAPEUTICS, INC.
         
      By: /s/ Douglas E. Onsi
      Name: Douglas E. Onsi
      Title: Chief Executive Officer and President

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Christopher Mirabelli and Douglas Onsi, and each of them, as his true and lawful attorney-in-fact and agent with full power of substitution, for him in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
    /s/ Douglas E. Onsi   Chief Executive Officer, President, Chief Financial Officer and Director (Principal Executive Officer and Principal Financial and Accounting Officer)   November 6, 2024
    Douglas E. Onsi        
             
    /s/ Christopher K. Mirabelli   Director and Chair   November 6, 2024
    Christopher K. Mirabelli, Ph.D.        
             
    /s/ James Cavanaugh   Director   November 6, 2024
    James Cavanaugh, Ph.D.        
             
    /s/ Thomas Dietz   Director   November 6, 2024
    Thomas Dietz, Ph.D.        
             
    /s/ William Li   Director   November 6, 2024
    William Li, M.D.        
             
    /s/ Joseph Loscalzo   Director   November 6, 2024
    Joseph Loscalzo, M.D., Ph.D.        
             
    /s/ Patricia Martin   Director   November 6, 2024
    Patricia Martin        
             
    /s/ Nissim Mashiach   Director   November 6, 2024
    Nissim Mashiach        
             
    /s/ Christian Richard   Director   November 6, 2024
    Christian Richard        
             
    /s/ Richard L. Schilsky   Director   November 6, 2024
    Richard L. Schilsky, M.D.        

     

     

     

    Get the next $LPTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LPTX

    DatePrice TargetRatingAnalyst
    1/29/2025Buy → Neutral
    H.C. Wainwright
    1/29/2025$9.00 → $1.25Outperform → Neutral
    Robert W. Baird
    6/28/2024$8.00Buy
    Rodman & Renshaw
    10/4/2021$6.00Buy
    Mizuho
    9/14/2021$3.00 → $4.00Outperform
    Raymond James
    More analyst ratings

    $LPTX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Leap Therapeutics Inc.

    DEFA14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

    11/12/25 4:10:30 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

    11/12/25 4:06:53 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Leap Therapeutics Inc.

    424B5 - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

    11/12/25 9:13:40 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leap Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Leap Therapeutics from Buy to Neutral

    1/29/25 7:15:39 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Leap Therapeutics from Outperform to Neutral and set a new price target of $1.25 from $9.00 previously

    1/29/25 7:15:19 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Leap Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $8.00

    6/28/24 8:18:39 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO,CFO,Pres.,GC,Treas.&Sec. Onsi Douglas E

    4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)

    11/13/25 5:02:26 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Li William

    4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)

    11/13/25 5:01:01 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Richard Christian M

    4 - CYPHERPUNK TECHNOLOGIES INC. (0001509745) (Issuer)

    11/13/25 4:59:45 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

    CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (NASDAQ:LPTX), a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash, today reported financial results for the third quarter of 2025 and a corporate update. As announced earlier today, the Company has changed its name to "Cypherpunk Technologies Inc." from "Leap Therapeutics, Inc." to reflect the strategic focus on acquiring the digital asset, ZEC, participating in the development of Zcash, and the values of privacy and liberty. The Company will begin trading on the Nasdaq Capital Market under the

    11/12/25 8:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

    Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies Inc. announces acquisition of 203,775.27 ZEC. CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced it will change its name to Cypherpunk Technologies Inc., and unveiled a digital asset treasury strategy to accumulate Zcash's native coin, ZEC. Cypherpunk has to date used $50 million of proceeds from the previously announced private placement to purchase 203,775.27 ZEC at an average purchase price of $245.37 per ZEC. In addition, the company also plans to change its ticker symbol to (NASDAQ:CYPH) as part of t

    11/12/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

    Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to continue supporting development of sirexatamab in DKK1-high CRC patients CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and ch

    10/20/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    Financials

    Live finance-specific insights

    View All

    Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

    CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (NASDAQ:LPTX), a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash, today reported financial results for the third quarter of 2025 and a corporate update. As announced earlier today, the Company has changed its name to "Cypherpunk Technologies Inc." from "Leap Therapeutics, Inc." to reflect the strategic focus on acquiring the digital asset, ZEC, participating in the development of Zcash, and the values of privacy and liberty. The Company will begin trading on the Nasdaq Capital Market under the

    11/12/25 8:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

    Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to continue supporting development of sirexatamab in DKK1-high CRC patients CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and ch

    10/20/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

    CAMBRIDGE, Mass., Oct. 6, 2025 /PRNewswire/ -- Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888 in cash commitments for a private investment in public equity ("PIPE") offering led by Winklevoss Capital to initiate a digital asset treasury strategy. Leap has entered into a securities purchase agreement for the purchase and sale of (i) 95,849,353 shares of common stock (the "Purchased Shares") or pre-funded warrants in lieu thereof (the "Purchased Pre-Funded Warrants") and (ii) warrants to purchase an additional 71,887,008 shares of common stock at an exercise price of $0.5335 per share (the "P

    10/6/25 9:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    Leadership Updates

    Live Leadership Updates

    View All

    Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

    Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies Inc. announces acquisition of 203,775.27 ZEC. CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced it will change its name to Cypherpunk Technologies Inc., and unveiled a digital asset treasury strategy to accumulate Zcash's native coin, ZEC. Cypherpunk has to date used $50 million of proceeds from the previously announced private placement to purchase 203,775.27 ZEC at an average purchase price of $245.37 per ZEC. In addition, the company also plans to change its ticker symbol to (NASDAQ:CYPH) as part of t

    11/12/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

    CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers. "We are honored to welcome Dr. Schilsky, who brings a wealth of experience and deep knowledge to bolster Leap's drug development strategy," said Christopher Mirabelli, PhD, Chairman of Leap Therapeutics' Board. "He is a

    9/6/22 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Leap Therapeutics Inc.

    SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

    11/14/24 6:07:56 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Leap Therapeutics Inc.

    SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

    4/25/24 8:39:23 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Leap Therapeutics Inc.

    SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

    4/19/24 4:31:26 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care